• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结石形成抑制剂。

Inhibitors of stone formation.

作者信息

Worcester E M

机构信息

Department of Medicine, Department of Veterans Affairs Medical Center, Milwaukee, WI 53295, USA.

出版信息

Semin Nephrol. 1996 Sep;16(5):474-86.

PMID:8890402
Abstract

Urine contains substances that inhibit the nucleation, growth, aggregation, and cell attachment of crystals. These may function to protect the kidney against the possibility of pathological calcification in tubular fluid and urine, which are generally supersaturated with respect to calcium salts, thereby preventing stone formation. Effects on calcium oxalate are the best studied, and most of the inhibitory activity resides in macromolecules such as glycoproteins and glycosaminoglycans. Inhibitory proteins found in urine include nephrocalcin, Tamm-Horsfall protein, uropontin, crystal matrix protein (F1 prothrombin fragment), and uronic acid-rich protein (bikunin). Most of the molecules are anionic, with many acidic amino acid residues, frequently contain post-translational modifications such as phosphorylation and glycosylation, and appear to exert their effects by binding to calcium oxalate surface. The specific structural motifs that favor crystal binding and inhibition are not yet known. A number of the proteins are made by renal epithelial cells, whereas others gain access to the urine by glomerular filtration. In a number of cases, abnormalities of protein structure or function have been found in stone formers. It is not yet known what proportion of stone formers have an abnormality of inhibitor function.

摘要

尿液中含有抑制晶体成核、生长、聚集及细胞附着的物质。这些物质可能起到保护肾脏的作用,防止肾小管液和尿液中出现病理性钙化,因为肾小管液和尿液通常相对于钙盐处于过饱和状态,从而预防结石形成。对草酸钙的影响研究得最为充分,且大部分抑制活性存在于糖蛋白和糖胺聚糖等大分子中。尿液中发现的抑制性蛋白质包括肾钙蛋白、Tamm-Horsfall蛋白、尿桥蛋白、晶体基质蛋白(F1凝血酶原片段)和富含糖醛酸的蛋白质(比 Kunin)。大多数分子呈阴离子性,含有许多酸性氨基酸残基,经常含有磷酸化和糖基化等翻译后修饰,并且似乎通过与草酸钙表面结合发挥作用。目前尚不清楚有利于晶体结合和抑制的具体结构基序。许多蛋白质由肾上皮细胞产生,而其他一些蛋白质则通过肾小球滤过进入尿液。在许多情况下,已在结石形成者中发现蛋白质结构或功能异常。目前尚不清楚结石形成者中抑制剂功能异常的比例是多少。

相似文献

1
Inhibitors of stone formation.结石形成抑制剂。
Semin Nephrol. 1996 Sep;16(5):474-86.
2
Urinary calcium oxalate crystal growth inhibitors.草酸钙尿结石晶体生长抑制剂。
J Am Soc Nephrol. 1994 Nov;5(5 Suppl 1):S46-53. doi: 10.1681/ASN.V55s46.
3
[Uronic-acid-rich protein: a new glycoprotein inhibiting the crystallization of calcium oxalate in vitro].富含糖醛酸的蛋白质:一种新型糖蛋白在体外抑制草酸钙结晶
Nephrologie. 1996;17(3):157-62.
4
Glycoprotein calcium oxalate crystal growth inhibitor in urine.尿液中的糖蛋白草酸钙晶体生长抑制剂。
Miner Electrolyte Metab. 1987;13(4):267-72.
5
[Glycoprotein inhibitors of urinary calculi formation].
Nephrologie. 1993;14(4):183-7.
6
Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis.肾钙素在抑制草酸钙结晶和肾结石形成中的作用。
Miner Electrolyte Metab. 1994;20(6):378-84.
7
Uropontin in urinary calcium stone formation.
Miner Electrolyte Metab. 1994;20(6):385-92.
8
Inter-alpha-inhibitor: a protein family involved in the inhibition of calcium oxalate crystallization.α-间抑制素:一个参与抑制草酸钙结晶的蛋白质家族。
Scanning Microsc. 1996;10(2):425-33; discussion 433-4.
9
Fibronectin as a potent inhibitor of calcium oxalate urolithiasis.纤连蛋白作为草酸钙尿路结石的有效抑制剂。
J Urol. 2000 Nov;164(5):1718-23.
10
Modulators of urinary stone formation.尿路结石形成的调节剂。
Front Biosci. 2004 May 1;9:1450-82. doi: 10.2741/1347.

引用本文的文献

1
Bio-inspired multifunctional disruptors of calcium oxalate crystallization.受生物启发的草酸钙结晶多功能干扰剂。
Nat Commun. 2025 Jun 5;16(1):5229. doi: 10.1038/s41467-025-60320-4.
2
Comparison of cat and human calcium oxalate monohydrate kidney stone matrix proteomes.猫和人草酸钙一水肾结石基质蛋白质组的比较。
Urolithiasis. 2022 Dec;50(6):653-664. doi: 10.1007/s00240-022-01363-w. Epub 2022 Sep 30.
3
Abrogation of store-operated Ca entry protects against crystal-induced ER stress in human proximal tubular cells.抑制钙库操纵的钙内流可保护人近端肾小管细胞免受晶体诱导的内质网应激。
Cell Death Discov. 2019 Aug 5;5:124. doi: 10.1038/s41420-019-0203-5. eCollection 2019.
4
The role of macromolecules in the formation of kidney stones.大分子在肾结石形成中的作用。
Urolithiasis. 2017 Feb;45(1):57-74. doi: 10.1007/s00240-016-0948-8. Epub 2016 Dec 2.
5
Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques.基因工程小鼠模型肾乳头间质钙化:与兰德尔斑的关系。
Urolithiasis. 2015 Jan;43 Suppl 1(0 1):65-76. doi: 10.1007/s00240-014-0699-3. Epub 2014 Aug 6.
6
Involvement of VKORC1 in the inhibition of calcium oxalate crystal formation in HK-2 cells.维生素K环氧化物还原酶复合体亚单位1(VKORC1)参与抑制HK-2细胞中草酸钙晶体形成。
J Huazhong Univ Sci Technolog Med Sci. 2014 Jun;34(3):376-381. doi: 10.1007/s11596-014-1286-0. Epub 2014 Jun 18.
7
Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein.Tamm-Horsfall 蛋白缺失小鼠进行性肾乳头钙化和输尿管结石形成。
Am J Physiol Renal Physiol. 2010 Sep;299(3):F469-78. doi: 10.1152/ajprenal.00243.2010. Epub 2010 Jun 30.
8
Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning.通过磷酸化骨桥蛋白和聚天冬氨酸肽的选择性晶面结合调节二水合草酸钙晶体生长,显示出扇形(成分)分带导致的阻塞。
J Biol Chem. 2009 Aug 28;284(35):23491-501. doi: 10.1074/jbc.M109.021899. Epub 2009 Jul 6.
9
Inhibition of calcium oxalate crystallization by commercial human serum albumin and human urinary albumin isolated from two different race groups: evidence for possible molecular differences.市售人血清白蛋白及从两个不同种族群体分离出的人尿白蛋白对草酸钙结晶的抑制作用:可能存在分子差异的证据
Urol Res. 2006 Dec;34(6):373-80. doi: 10.1007/s00240-006-0070-4.
10
ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis.美国内科医师学会最佳实践第181号:肾结石的化学病理学临床研究与管理
J Clin Pathol. 2005 Feb;58(2):134-40. doi: 10.1136/jcp.2004.019588.